Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

PR Newswire January 4, 2022

Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index

PR Newswire December 16, 2021

Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presentations at ASH 2021

PR Newswire December 13, 2021

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

PR Newswire December 13, 2021

Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma

PR Newswire November 29, 2021

Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PR Newswire November 10, 2021

Viracta Therapeutics Secures $50 Million Credit Facility from Silicon Valley Bank and Oxford Finance

PR Newswire November 5, 2021

Viracta Therapeutics Announces Upcoming Oral and Poster Presentations at the 2021 American Society of Hematology Annual Meeting

PR Newswire November 4, 2021

Viracta Therapeutics to Present at Upcoming Investor Conferences

PR Newswire November 1, 2021

Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

PR Newswire October 6, 2021

Viracta Therapeutics to Present at Upcoming Investor Conferences in September

PR Newswire September 7, 2021

Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China

PR Newswire August 23, 2021

Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors

PR Newswire August 16, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

PR Newswire February 24, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

PR Newswire February 16, 2021

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

PR Newswire February 11, 2021

MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

ACCESSWIRE IA January 8, 2021

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of SNSS, LOAC, FBSS, and CPAH Mergers

GlobeNewswire January 7, 2021

ALERT: Halper Sadeh LLP Investigates TDY, TCP, BEAT, HCAP, SNSS; Shareholders Are Encouraged to Contact the Firm

PR Newswire January 5, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds HLIX, XLNX, SNSS, and AKER Shareholders About Its Ongoing Investigations

PR Newswire December 30, 2020